Orthocell Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Orthocell te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	15.3%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Sep 09

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Orthocell onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ASX:OCC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	5	-7	-7	-7	N/A
3/31/2024	5	-7	-7	-7	N/A
12/31/2023	5	-7	-7	-7	N/A
9/30/2023	5	-7	3	4	N/A
6/30/2023	4	-6	14	15	N/A
3/31/2023	3	-7	14	14	N/A
12/31/2022	2	-9	13	14	N/A
9/30/2022	2	-9	3	4	N/A
6/30/2022	2	-9	-7	-6	N/A
3/31/2022	1	-9	-6	-6	N/A
12/31/2021	1	-9	-6	-6	N/A
9/30/2021	1	-9	-5	-5	N/A
6/30/2021	1	-9	-5	-5	N/A
3/31/2021	1	-9	-4	-4	N/A
12/31/2020	1	-8	-4	-4	N/A
9/30/2020	1	-7	-5	-5	N/A
6/30/2020	1	-6	-5	-5	N/A
3/31/2020	1	-6	-7	-6	N/A
12/31/2019	1	-7	-8	-8	N/A
9/30/2019	1	-6	-6	-6	N/A
6/30/2019	1	-6	-5	-4	N/A
3/31/2019	1	-6	-5	-4	N/A
12/31/2018	1	-6	-5	-4	N/A
9/30/2018	1	-6	-5	-4	N/A
6/30/2018	1	-6	-5	-5	N/A
3/31/2018	1	-4	N/A	-3	N/A
12/31/2017	1	-2	N/A	-2	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-4	N/A	-4	N/A
3/31/2017	1	-4	N/A	-4	N/A
12/31/2016	1	-4	N/A	-4	N/A
9/30/2016	1	-4	N/A	-4	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-3	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-4	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-2	N/A	-2	N/A
3/31/2014	1	-2	N/A	-1	N/A
12/31/2013	1	-1	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van OCC boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van OCC naar verwachting sneller zal groeien dan de markt Australian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van OCC naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van OCC naar verwachting sneller zal groeien dan de markt Australian.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van OCC naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van OCC naar verwachting over 3 jaar hoog zal zijn

Orthocell Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.

CEO, MD & Executive Director exercised options to buy AU$190k worth of stock.

Orthocell Limited, Annual General Meeting, Nov 29, 2024

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023)

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven